SCHEMBL2906170

SCHEMBL2906170

COC(=O)C(C)(C)Cc1cc(C)c(OCCCBr)cc1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TSHR P16473 2/20 0.38
CYP2C9 P11712 2/20 0.38
TTR P02766 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C8 P10632 1/20 0.38
CHRM1 P11229 1/20 0.38
ADRA1A P35348 1/20 0.38
PPARG P37231 1/20 0.38
HTR2B P41595 1/20 0.38
SLCO1B3 Q9NPD5 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CISD1 Q9NZ45 1/20 0.38
SLCO1B1 Q9Y6L6 1/20 0.38
RAB9A P51151 1/20 0.36
MAPT P10636 3/20 0.35
KDM4E B2RXH2 5/20 0.33
KMT2A Q03164 2/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2905969 0.94 MAPT (0.36) PPARASMN1; SMN2TSHRCYP2C9TTR
SCHEMBL13210133 0.88 RARB (0.40) PPARASMN1; SMN2TSHRCYP2C9TTR
SCHEMBL3069062 0.80 RAB9A (0.41) PPARASMN1; SMN2TSHRCYP2C9TTR
SCHEMBL11092852 0.78 PPARA (0.55) PPARASMN1; SMN2TSHRCYP2C9TTR
SCHEMBL2905931 0.78 FFAR4 (0.46) SMN1; SMN2RAB9AKDM4ELMNAALDH1A1
SCHEMBL2904561 0.76 RAB9A (0.43) PPARASMN1; SMN2TSHRCYP2C9TTR
SCHEMBL2905725 0.75 CNR2 (0.38) SMN1; SMN2CYP2C9CYP1A2MAPTKDM4E
SCHEMBL26834272 0.73 TSHR (0.39) PPARASMN1; SMN2TSHRCYP2C9TTR
SCHEMBL2907451 0.73 RAB9A (0.39) PPARASMN1; SMN2TSHRCYP2C9TTR
SCHEMBL2906316 0.71 PPARA (0.45) PPARASMN1; SMN2TSHRCYP2C9TTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951692-B1 OXAZOLE AND THIAZOLE PPAR MODULATOR IRM LLC (BM) 2010-08-18 EP disclosed
US-20100048453-A1 OXAZOLE AND THIAZOLE PPAR MODULATOR IRM LLC (BM) 2010-02-25 US disclosed
US-20100048453-A1 OXAZOLE AND THIAZOLE PPAR MODULATOR IRM LLC (BM) 2010-02-25 US disclosed
US-20100048453-A1 OXAZOLE AND THIAZOLE PPAR MODULATOR IRM LLC (BM) 2010-02-25 US disclosed
EP-1951692-A1 OXAZOLE AND THIAZOLE PPAR MODULATOR IRM LLC (BM) 2008-08-06 EP disclosed
WO-2007056496-A1 OXAZOLE AND THIAZOLE PPAR MODULATOR IRM LLC (BM) 2007-05-18 WO disclosed
WO-2007056496-A1 OXAZOLE AND THIAZOLE PPAR MODULATOR IRM LLC (BM) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048453-A1 OXAZOLE AND THIAZOLE PPAR MODULATOR PPARD, PPARG, PPARA PPARA 3/4885SMN1; SMN2 4215/4885TSHR 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.